CSPC Pharmaceutical Group Limited has announced the appointment of Mr. Zhang Yiwei as an Executive Director, effective 2 March 2026. Mr. Zhang, aged 41, joined the Group in February 2026 and currently serves as Executive President, overseeing securities affairs. He has more than 17 years of investment banking experience, focusing on equity financing, debt financing, and mergers and acquisitions.

Prior to joining, Mr. Zhang served at SDIC Securities Co., Ltd. from July 2015 to January 2026, holding roles including Business Director and Executive General Manager of the Investment Banking Committee. He was also a member of its equity financing internal review committee. Earlier, he worked at Huatai United Securities Co., Ltd. from February 2008 to May 2015 as Business Director, participating in corporate bond issuance and private placement projects.

Mr. Zhang holds a Bachelor of Management in Human Resource Management and a Bachelor of Economics in International Economics and Trade from Beijing Normal University, both obtained in 2006. He subsequently attained a Master of Economics from The University of Hong Kong in 2007. He was a Registered Sponsor Representative in the People’s Republic of China from September 2015 to January 2026.

Under a three-year service contract, Mr. Zhang’s remuneration comprises a monthly salary of RMB0.06 million, an annual director’s fee of HKD0.06 million, and a performance-related discretionary bonus. He is subject to retirement and re-election at the annual general meeting in accordance with the Company’s articles of association. He currently does not have any interests in the shares of the Company and holds no other directorships in publicly listed companies. The Board has welcomed his appointment.